Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes
Rupert L. Mayer, Rein Verbeke, Caroline Asselman, Ilke Aernout, Adillah Gul, Denzel Eggermont, Katie Boucher, Fabien Théry, Teresa Mendes Maia, Hans Demol, Ralf Gabriels, Lennart Martens, Christophe Bécavin, Stefaan C. De Smedt, Bart Vandekerckhove, Ine Lentacker, Francis Impens
Abstract
Abstract Listeria monocytogenes is a foodborne intracellular bacterial pathogen leading to human listeriosis. Despite a high mortality rate and increasing antibiotic resistance no clinically approved vaccine against Listeria is available. Attenuated Listeria strains offer protection and are tested as antitumor vaccine vectors, but would benefit from a better knowledge on immunodominant vector antigens. To identify novel antigens, we screen for Listeria peptides presented on the surface of infected human cell lines by mass spectrometry-based immunopeptidomics. In between more than 15,000 human self-peptides, we detect 68 Listeria immunopeptides from 42 different bacterial proteins, including several known antigens. Peptides presented on different cell lines are often derived from the same bacterial surface proteins, classifying these antigens as potential vaccine candidates. Encoding these highly presented antigens in lipid nanoparticle mRNA vaccine formulations results in specific CD8 + T-cell responses and induces protection in vaccination challenge experiments in mice. Our results can serve as a starting point for the development of a clinical mRNA vaccine against Listeria and aid to improve attenuated Listeria vaccines and vectors, demonstrating the power of immunopeptidomics for next-generation bacterial vaccine development.